England to begin screening all newborns for spinal muscular atrophy by 2027

England will screen every newborn for spinal muscular atrophy starting 2027, enabling earlier treatment of a rare muscle-wasting disease.

Every baby born in England will be tested for spinal muscular atrophy (SMA) starting in 2027, a move campaigners are calling a landmark moment in the early detection and treatment of a rare but serious muscle-wasting disease. SMA is a genetic condition that causes progressive muscle weakness and, in its most severe forms, can be life-threatening in infancy. Early detection is critical because treatments are significantly more effective when started before symptoms appear. The expansion adds SMA to England's existing newborn blood-spot screening programme, which already tests for a range of conditions shortly after birth. However, the announcement has also prompted calls to go further: Dr Janet Hoskin and others argue that other serious genetic conditions — including Duchenne muscular dystrophy — should similarly be added to the screening programme.

Why it matters

Newborn screening for SMA can enable treatment before irreversible muscle damage occurs, potentially transforming outcomes for affected children. The debate it has sparked highlights broader questions about which genetic conditions should qualify for universal screening across England.

What's next

Dr Hoskin and other advocates are pushing for the screening programme to be broadened further to include other serious genetic conditions such as Duchenne muscular dystrophy.

Key facts

• Universal newborn screening for spinal muscular atrophy in England is set to begin in 2027
• SMA is a rare genetic muscle-wasting disease that can be fatal in its severest form during infancy
• Campaigners described the policy change as a 'landmark moment'
• Dr Janet Hoskin has written to The Guardian calling for other conditions, including Duchenne muscular dystrophy, to also be included in newborn screening
• Early treatment of SMA is substantially more effective when started before symptoms appear

Bias & framing notes

Both sources are from The Guardian. The news report frames the policy change positively, leading with campaigners' celebratory language. The letter from Dr Hoskin provides a mild counterpoint by questioning whether the programme goes far enough, but neither source presents any opposition to the SMA screening announcement itself. The stated rationale for the policy is implied rather than quoted directly from officials.

NewsClear — neutral news & congressional tracking · Bill of the Week